FDA Takes Action Against Unapproved Narcotic Products

The FDA is cracking down on certain unapproved narcotic products that are currently on the market. It's possible that some lymphoma patients are taking these right now and are may soon find themselves unable to fill their prescriptions.

What has happened? Some pharmaceutical companies have been creating narcotic pain medications in dosages that the FDA has not approved. There is nothing wrong or bad about the ingredients in these products—it's merely the dosage amount in them to which the FDA objects, because they haven't approved them.

What are the drugs? The unapproved medications feature three serious, Schedule II narcotics: Morphine sulfate, hydromorphone, and oxycodone. These are the active narcotic agents in approved drugs such as Dilaudid (hydromorphone) and Percocet (oxycodone).

What does this mean to me if I take one of these medications? It means that in 60-90 days your physician will have to prescribe you a different version of the drug. It will still contain the same active ingredient(s) as before, but the dosage level may change, something your physician will have to take into account when prescribing you a new medication.

How can I find out if I'm taking one of these products? The FDA has a list of the unapproved products that you can access here.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap